Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Steven W. Pipe, Amy L. Dunn & Guy Young. (2023) Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors. Expert Review of Hematology 0:0, pages 1-15.
Read now
Read now
Pooja Gogia, Michael Tarantino, Wolfgang Schramm & Louis Aledort. (2023) New directions to develop therapies for people with hemophilia. Expert Review of Hematology 16:6, pages 417-433.
Read now
Read now
Eman Hassan & Jayashree Motwani. (2022) Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review. Pediatric Hematology and Oncology 39:5, pages 418-426.
Read now
Read now
Articles from other publishers (9)
Yu-lu Liu, Xiao-xia Zhu, Li-yun Niu, Ya Gao, Hui GAN, Zhuo-na Wu, Jian LI, Su-xiang Feng, Gui-fang Dou, Ruo-lan Gu & Zhi-yun Meng. (2023) The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice. Journal of Pharmaceutical Sciences 112:3, pages 877-883.
Crossref
Crossref
Ricardo Mesquita Camelo, Mariana Michel Barbosa, Maiara Silva Araújo, Roberto Lúcio MunizJr.Jr., Augusto Afonso GuerraJr.Jr., Brian Godman, Suely Meireles Rezende, Francisco de Assis Acurcio, Antony P. Martin & Juliana Alvares-Teodoro. (2023) Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab. Value in Health Regional Issues 34, pages 31-39.
Crossref
Crossref
Flora Peyvandi, Kaan Kavakli, Amal El‐Beshlawy & Savita Rangarajan. (2022) Management of haemophilia A with inhibitors: A regional cross‐talk. Haemophilia 28:6, pages 950-961.
Crossref
Crossref
Dunia Castillo-Gonzàles, Irianys Álvarez Sardiñas, Consuelo Macías Abraham & Alex G. Muñoz Bedoya. (2022) Emicizumab in hemophilia A with inhibitors: clinical and economic impact of its use in a Cuban patient. AboutOpen 9, pages 83-86.
Crossref
Crossref
Katharina Holstein, Sandra Le Quellec, Robert Klamroth, Angelika Batorova, Pål Andre Holme, Victor Jiménez‐Yuste & Jan Astermark. (2021) Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?. Haemophilia 28:2, pages 215-222.
Crossref
Crossref
Eman Hassan, Jonathan Lancashire & Jayashree Motwani. (2021) Patients on emicizumab prophylaxis with previously tolerized inhibitors: Is there a risk of inhibitors recurrence?. Haemophilia 28:2.
Crossref
Crossref
Archana Hinduja, Sherraine Della-Moretta & Payal Desai. 2022. Transfusion Practice in Clinical Neurosciences. Transfusion Practice in Clinical Neurosciences
525
539
.
Patrick Ellsworth & Alice Ma. (2021) Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?. Hematology 2021:1, pages 219-225.
Crossref
Crossref
Elizabeth Davies, Luke Carter-Brzezinski, Margarita Traintafillou, Rachel Brown & Charles R M Hay. (2021) Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report. The Journal of Haemophilia Practice 8:1, pages 136-140.
Crossref
Crossref